References
- Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. https://doi.org/10.1001/jama.293.17.2126
- Blich M, Zeidan-Shwiri T, Petcherski S, Osherov A, Hammerman H. Incidence, predictors and outcome of drug-eluting stent thrombosis in real- world practice. J Invasive Cardiol 2010;22:461-4.
- Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program 2010;2010:144-9. https://doi.org/10.1182/asheducation-2010.1.144
- Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839-47. https://doi.org/10.1200/JCO.2009.22.3271
- De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004;50:187-96. https://doi.org/10.1016/j.critrevonc.2003.10.003
- Nakagawa T, Yasuno M, Tanahashi H, et al. A case of acute myocardial infarction: intracoronary thrombosis in two major coronary arteries due to hormone therapy. Angiology 1994;45:333-8. https://doi.org/10.1177/000331979404500501
- Canale ML, Camerini A, Stroppa S, et al. A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med (Hagerstown) 2006;7:835-7. https://doi.org/10.2459/01.JCM.0000250874.09273.9b
- Wijesinghe N, Thompson PI, McAlister H. Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006;15:337-9. https://doi.org/10.1016/j.hlc.2006.03.010
- Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy: a case report. Angiology 1999;50:1021-5. https://doi.org/10.1177/000331979905001208
- Gemici G, Cinçin A, Degertekin M, Oktay A. Paclitaxel-induced ST-segment elevations. Clin Cardiol 2009;32:E94-6. https://doi.org/10.1002/clc.20291
- Lee SP, Suh JW, Park KW, et al. Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: a multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease. Trials 2010;11:87. https://doi.org/10.1186/1745-6215-11-87
- Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the respond study. Circulation 2010;121:1188-99. https://doi.org/10.1161/CIRCULATIONAHA.109.919456
- Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31. https://doi.org/10.1016/S0140-6736(09)60441-4
Cited by
- Management of CAD in Patients with Active Cancer: the Interventional Cardiologists’ Perspective vol.19, pp.6, 2012, https://doi.org/10.1007/s11886-017-0862-x
- Treatment of coronary artery disease in cancer survivors: an emerging challenge vol.28, pp.1, 2012, https://doi.org/10.1097/mca.0000000000000444
- Acute Coronary Syndrome in Cancer Patients vol.18, pp.5, 2012, https://doi.org/10.1007/s40256-018-0286-z
- Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges vol.20, pp.6, 2012, https://doi.org/10.1007/s11864-019-0644-3